Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42803-42812

  Park, Silvia ^a   Jung, Chul Won ^a   Kim, Kihyun ^a   Kim, Seok Jin ^a   Kim, Won Seog ^a   Jang, Jun Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anemia; Cancer; Hepcidin; Soluble transferrin receptor

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; TRANSFERRIN RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; METASTASIS; MICROCYTIC ANEMIA; MOLECULARLY TARGETED THERAPY; STOMACH CANCER; BLOOD; COMPLICATION; ERYTHROPOIESIS; INCIDENCE; METABOLISM; MIDDLE AGED; NEOPLASM; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; C-REACTIVE PROTEIN; ERYTHROPOIESIS; FEMALE; FERRITINS; HEPCIDINS; HUMANS; INCIDENCE; IRON; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TRANSFERRIN;

EID: 84952342490     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5658     Document Type: Article

References (57)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116:11S-26S.
2. Henry DH. Parenteral iron therapy in cancer-associated anemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:351-356.
3. Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol. 2004; 180:45-51.
4. Hoff CM, Lassen P, Eriksen JG, Hansen HS, Specht L, Overgaard M, Grau C, Johansen J, Bentzen J, Andersen L, Evensen JF, Overgaard J. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy?-results from the randomized DAHANCA 5 and 7 trials. Acta Oncol. 2011; 50:1006-1014.
5. Gordon MS. Managing anemia in the cancer patient: old problems, future solutions. Oncologist. 2002; 7:331-341.
6. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000; 26:303-311.
7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91:1616-1634.
8. Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol. 2000; 64:353-358.
9. Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol. 1999; 70:7-12.
10. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant. 1999; 14:85-92.
11. Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia?. J Clin Oncol. 2008; 26:1022-1024.
12. Cartwright GE. The anemia of chronic disorders. Semin Hematol. 1966; 3:351-375.
13. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989; 299:157-158.
14. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013; 161:639-648.
15. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102:783-788.
16. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D'Alo F, Larocca LM, Raymakers RA, Swinkels DW, Voso MT, Leone G. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol. 2010; 28:2538-2543.
17. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012; 23:1954-1962.
18. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ, Wurz E, Datz C, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009; 113:5277-5286.
19. Pham CM, Syed AA, Siddiqui HA, Keller RA, Kowalewski C. Case of metastatic basal cell carcinoma to bone marrow, resulting in myelophthisic anemia. Am J Dermatopathol. 2013; 35:e34-36.
20. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm. 2007; 64:S5-13. quiz S28-30.
21. Zhu A, Kaneshiro M, Kaunitz JD. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Dig Dis Sci. 2010; 55:548-559.
22. (NCCN) NCCN. Cancer-and Chemotherapy-Induced Anemia. NCCN Clinical Practice Guidelines in Oncology. Version 32014.
23. Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clin Chem. 2003; 49:175-178.
24. Bross R, Zitterkoph J, Pithia J, Benner D, Rambod M, Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009; 29:571-581.
25. Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, Luft FC. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis. 1998; 31:263-272.
26. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011; 57:1650-1669.
27. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008; 93:90-97.
28. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003; 329:9-22.
29. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997; 89:1052-1057.
30. Speeckaert MM, Speeckaert R, Delanghe JR. Biological and clinical aspects of soluble transferrin receptor. Crit Rev Clin Lab Sci. 2010; 47:213-228.
31. Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med. 1994; 121:278-300.
32. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009; 14:43-56.
33. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;:CD005033.
34. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19:2865-2874.
35. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94:1211-1220.
36. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12:CD003407.
37. Administration FaD. Epetin alfa label. Accessed May 22:2013.
38. Administration FaD. Darbepoetin alfa label. Accesssed May 22:2013.
39. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008; 26:1611-1618.
40. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26:1619-1625.
41. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann Oncol. 2013; 24:475-482.
42. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12:231-242.
43. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010; 116:522-525.
44. Dawson AA, Ogston D. Factors influencing the prognosis in myelomatosis. Postgrad Med J. 1971; 47:635-638.
45. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, Chiang JH, Lui WY, Chu CW, Lee SD. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology. 2002; 49:1315-1319.
46. Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009; 15:S50-59.
47. Jang JW. Current status of liver diseases in Korea: liver cirrhosis. Korean J Hepatol. 2009; 15:S40-49.
48. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol. 2009; 15:S13-24.
49. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40:2293-2306.
50. Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008; 159-165.
51. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006; 1:S4-8.
52. Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol. 2010; 2010:508739.
53. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood. 1990; 75:1870-1876.
54. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013; 165:575-582. e573.
55. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011; 58:1241-1251.
56. Ludwig H, Muldur E, Endler G, Hubl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013; 24:1886-1892.
57. Suominen P, Mottonen T, Rajamaki A, Irjala K. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2000; 43:1016-1020.